The human dopamine D 2L receptor couples promiscuously to multiple members of the G␣ i/o subfamily. Despite the high homology of the D 2L and D 3 receptors, the G protein coupling specificity of the human D 3 receptor is less clearly characterized. The primary aim of this study, then, was the parallel characterization of the G protein coupling specificity of the D 2L and D 3 receptors. By using both receptor-G protein fusion proteins and stable cell lines in which pertussis toxin-resistant mutants of individual G␣ i -family G proteins were expressed in an inducible fashion, we demonstrated highly selective coupling of the D 3 receptor to G␣ o1 . Furthermore, by using the fusion proteins to ensure identical stoichiometry of receptor to G protein for each pairing, a range of ligands displayed higher potency and, for partial agonists, higher efficacy at the D 3 receptor when coupled to G␣ o1 compared with the D 2L receptor. The second aim of this study was to investigate the molecular basis of the above differential G protein coupling specificity. The importance of a 12-amino acid sequence from the C-terminal end of the third intracellular loop of the D 2L receptor in providing promiscuity in G protein coupling was demonstrated using a chimeric D 3 /D 2 receptor in which the equivalent region of the D 3 receptor was exchanged for this sequence. This chimera displayed D 3 -like affinity for [ 3 H]spiperone and potency for agonists but gained D 2 -like ability to couple to each of G␣ i1-3 as well as G␣ o1 .
In recent studies, we have shown that the long isoform of the human dopamine D 2 receptor (D 2L receptor) couples efficiently and promiscuously to all four G␣ i/o subtypes . This confirmed previous work by other groups, although the relative order of preference remains controversial (Watts et al., 1998; Jiang et al., 2001; Gazi et al., 2003; Senogles et al., 2004) . Although the D 2 receptor is considered a key target for antipsychotic drugs, there has been considerable interest in the contribution that the dopamine D 3 receptor may provide (Gurevich et al., 1997; Joyce, 2001; Joyce and Millan, 2005; Sokoloff et al., 2006) . Human dopamine D 2 and D 3 receptors have an overall amino acid similarity of 52%, which increases to 78% if only transmembrane regions are considered (Sokoloff et al., 1990) . As a result, D 2 and D 3 receptors exhibit a similar pharmacological profile (Ahlgren-Beckendorf and Levant, 2004) . However, signal transduction by the D 3 receptor is less clearly understood than that of the D 2 receptor. Studies to elucidate cellular responses to D 3 receptor activation are hampered by the coexpression of D 2 and D 3 receptors in brain tissue and the lack of definitively selective pharmacological tools. It follows, then, that the majority of data have been obtained by expression of the receptors in heterologous systems. Initial reports indicated that the D 3 receptor, when expressed in a variety of cell systems, did not exhibit a decrease in affinity for agonists in the presence of guanine nucleotides and did not modulate adenylate cyclase activity (Sokoloff et al., 1990; Freedman et al., 1994; Tang et al., 1994) . However, more recently, it has been shown that dopaminergic agonists dose-dependently stimulate guanosine 5Ј-O-(thiotriphosphate) ([ 35 S]GTP␥S) binding in Sf-9 insect cells (Alberts et al., 2000) , Chinese hamster ovary cells (Malmberg et al., 1998; Newman-Tancredi et al., 1999; Vanhauwe et al., 1999; Vanhauwe et al., 2000) , and SH-SY5Y human neuroblastoma cells (Zaworski et al., 1999) in which the D 3 receptor was expressed. Because these effects were abolished by pertussis toxin treatment, they must reflect activation of one, or more, members of the "G i " G protein family. The first objective of this study, therefore, was to elucidate, in parallel, the coupling specificities of both D 2L and D 3 dopamine receptors. As with a recent study of a functionally selective ligand at the D 2L receptor , the need to devise model systems in which the interaction between a specific receptor and G protein could be studied in isolation was crucial. To this end, pertussis toxinresistant variants of G␣ i/o G proteins were used. Likewise, it was vital to control the relative expression levels of both receptor and G protein. Both receptor-G protein fusion proteins and Flp-In T-REx HEK293 cell lines, in which the receptor was constitutively expressed while the G protein could be expressed from the inducible Flp-In locus, were used . Using these strategies, we confirm the promiscuous coupling of the D 2L receptor to G␣ i1 , G␣ i2 , G␣ i3 , and G␣ o1 . Furthermore, the efficient and specific coupling of D 3 to G␣ o1 but not G␣ i1 , G␣ i2 , and G␣ i3 was demonstrated, as well as differences in ligand potency and efficacy, particularly for S-(Ϫ)-3-PPP, which has recently been described as a functionally selective agonist at the D 2L receptor .
The second aim of this study was to investigate the molecular basis of the differential G protein-coupling specificities of the dopamine D 2L and D 3 receptors. To investigate regions within receptors that are important in directing potential differences in G protein interaction selectivity, an accepted approach is the use of chimeric constructs in which one region of a donor receptor is replaced with the equivalent region of a homologous, acceptor receptor. We used a previously studied D 3 /D 2 receptor chimera (Filteau et al., 1999) , here termed D 3/2 , that has the backbone of the D 3 dopamine receptor but with a 12-amino acid section of D 2 at the end of the third intracellular loop replacing the equivalent D 3 sequence. This chimeric D 3/2 receptor had the capacity to couple to each of G␣ i1 , G␣ i2 , G␣ i3 , and G␣ o1 . Pharmacological analysis indicated that the D 3/2 receptor displayed D 3 -like affinity for [ 3 H]spiperone (Robinson and Caron, 1996) but D 2 -like ability to couple to each of G␣ i1-3 as well as G␣ o1 in response to dopamine. However, detailed pharmacological studies indicated that the swapped segment of the third intracellular loop was insufficient to fully define the capacity of agonists other than dopamine to activate multiple G proteins. tyramine, hydroxy-N-n-propylnorapomorphine (NPA), 7-OH-DPAT, and GTP␥S were purchased from Sigma Chemical (Poole, Dorset, UK). Spiperone hydrochloride was from Tocris Cookson Inc. (Bristol, UK). Oligonucleotides were obtained from Thermo Electron GmbH (Ulm, Germany), and all materials for tissue culture were from Invitrogen (Paisley, UK). All other reagents were obtained as indicated.
Materials and Methods
D 3 and D 3/2 Receptor Subcloning into pcDNA3. cDNA of the human D 3 dopamine receptor and the chimeric D 3/2 dopamine receptor were initially in the vectors pRC and pcDNA3.1, respectively. The two cDNAs were amplified by PCR using the following primers: sense, CCC AAG CTT ATG GCA TCT CTG AGT CAG CTG; and antisense, AAA AAA AAC CAT GGA AGA CAG GAT CTT GAG GAA GGC. Underlined bases indicate the restriction sites HindIII (sense) and XhoI (antisense). The resulting PCR fragments were digested with HindIII and XhoI and inserted into pcDNA3. D 2L Receptor Subcloning into pcDNA3. D 2L was initially in the vector pDEST12.2. D 2L cDNA was amplified by PCR using the following primers: sense, AAA AGA ATC CGC CAC CAT GGA TCC ACT GAA TCT GTC C; and antisense, AAA ACT CGA GTC AGC AGT GGA GGA TCT TCA GGA AGG. Underlined bases indicate the restriction sites EcoRI (sense) and XhoI (antisense). The resulting PCR fragment was digested with EcoRI and XhoI and inserted into pcDNA3.
Construction of the Myc-D 2L -G-Protein ␣ Subunit Fusion Proteins. The construction of Myc-D 2L -G protein ␣ subunit fusion proteins have been described previously . Pertussis toxin-resistant ␣ 2A -adrenoceptor-G protein fusion proteins were prepared as described previously (Wise and Milligan, 1997) . In brief, Cys351 of rat G␣ i1 , G␣ i3 , and G␣ o1 (or Cys352 in G␣ i2 ) was mutated to isoleucine by site-directed mutagenesis and then used to create the ␣ 2A -adrenoceptor-G␣ fusion proteins using the porcine ␣ 2A -adrenoceptor in pcDNA3. These constructs were cloned into pcDNA3 using created 5Ј KpnI and 3Ј EcoRI sites, with an NcoI site between receptor and G protein ␣ subunit cDNAs. To create D 2L -G protein ␣ subunit proteins, the ␣ 2A -adrenoceptor-G␣ fusion proteins (NcoI) were excised from pcDNA3 using KpnI and EcoRI, digested with NcoI, and the G␣ subunit cDNA was purified. The G␣ i subunit cDNAs were then cloned into pcDNA3 with the Myc-D 2L PCR fragment to create the four D 2L -G protein ␣ subunit fusion proteins.
Construction of the Myc-D 3 /D 3/2 -G-Protein ␣ Subunit Fusion Proteins. Primers encoding the Myc epitope sequence were used to generate N-terminally tagged Myc-D 3 and Myc-D 3/2 and remove the stop codon: sense, 5Ј-AAA AAA AG GTA CCA TGG AAC AAA AAC TTA TTT CTG AAG AAG ATC TGG CAT CTC TGA GTC AGC TGA GTA GC-3Ј; and antisense, 5Ј-AAA AAA AAC CAT GGA AGA CAG GAT CTT GAG GAA GGC-3Ј. Underlined bases indicate introduced restriction sites (sense, KpnI; antisense, NcoI), and bases in bold indicate introduced N-terminal Myc tag. The PCR fragment was digested using KpnI and NcoI. As for D 2L , G␣ i subunit cDNAs were purified and cloned into pcDNA3 with the Myc-D 3 or Myc-D 3/2 PCR fragment to create four D 3 -G protein ␣ subunit fusion proteins and four D 3/2 -G protein ␣ subunit fusion proteins. All PCR fragments were sequenced in their entirety.
Flp-In Constructs. The previously described pertussis toxinresistant mutants of rat G␣ i1 , G␣ i2 , G␣ i3 , and G␣ o1 were cloned into pcDNA3. cDNAs were excised using KpnI and ApaI (G␣ i1-3 ) or ApaI (G␣ o1 ) and subcloned into the pcDNA5/FRT/TO vector (Invitrogen).
Cell Culture and Transfection. HEK293 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 0.292 g/l L-glutamine and 10% (v/v) newborn calf serum at 37°C in a 5% CO 2 humidified atmosphere. Cells were grown to 60 to 80% confluence before transient transfection. Transfection was performed using Lipofectamine transfection reagent (Invitrogen) according to the manufacturer's instructions.
Generation of Stable Flp-In T-REx HEK293 Cells. To generate Flp-In T-REx HEK293 cells able to inducibly express the G protein ␣ subunit of interest, the cells were transfected with a mixture containing the desired G protein ␣ subunit cDNA in the pcDNA5/FRT/TO vector and pOG44 vectors (1:9) using Lipofectamine according to the manufacturer's instructions. Cell maintenance and selection were as described previously (Milasta et al., 2006) . Clones were screened for G protein expression by Western blotting. To constitutively stably coexpress D 2L , D 3 , or D 3/2 in G protein-inducible cell lines, the appropriate cells were further transfected with D 2L , D 3 , or D 3/2 cDNA in pcDNA3 as described above, and resistant cells were selected in the presence of 1 mg/ml G418. Resistant clones were screened for receptor expression using specific [ 3 H]spiperone binding. Cells were treated with 1 g/ml tetracycline 24 to 48 h before assay to induce expression of the G protein ␣ subunit cloned into the Flp-In locus.
Membrane Preparation. Cells were collected by centrifugation (1700g, 5 min, 4°C), frozen at Ϫ80°C for at least 1 h, and resuspended in 15 ml of buffer (10 mM Tris, 0.1 mM EDTA, pH 7.4). Cell suspensions were then homogenized using an Ultra Turrax three times for 20 s. The homogenate was centrifuged at 1700g for 10 min, and the supernatant was collected and centrifuged at 48,000g for 45 min at 4°C. The resulting pellet was resuspended in buffer and stored at Ϫ80°C in aliquots of 1 ml.
Saturation Binding Assays Using [ 3 H]Spiperone. Cell membranes (10 g of protein) were incubated in triplicate with [ 3 H]spiperone (0.001-2 nM) in a total volume of 1 ml of buffer (20 mM HEPES, 6 mM MgCl 2 , 1 mM EDTA, 1 mM EGTA, pH 7.4). Nonspecific binding was determined by the inclusion of 10 M (ϩ)-butaclamol. The reaction was initiated by the addition of membranes, and the tubes were incubated at 25°C for 3 h. The reaction was terminated by rapid filtration using a Brandel cell harvester with three 5-ml washes of ice-cold phosphate-buffered saline (140 mM NaCl, 10 mM KCl, 1.5 mM KH 2 PO 4 , 8 mM Na 2 HPO 4 ). The filters were soaked in 3 ml of scintillation fluid, and radioactivity present was determined by liquid scintillation spectrometry.
[ 35 S]GTP␥S Binding Assays. Cell membranes (10 g) were incubated in 900 l of buffer (20 mM HEPES, 100 mM NaCl, 6 mM MgCl 2 , 40 M ascorbic acid, pH 7.4) containing 10 M GDP and various concentrations of ligands. All experiments were performed in triplicate. The reaction was initiated by the addition of cell membranes and incubated at 30°C for 30 min. A 100-l volume of [ 35 S]GTP␥S (0.1 nM final concentration) was then added, and the incubation was continued for a further 30 min. The reaction was terminated by rapid filtration with a Brandel cell harvester and three 4-ml washes with ice-cold phosphate-buffered saline. Radioactivity was determined as described for saturation analysis. 35 S]GTP␥S) in the presence or absence of dopamine (10 M). Nonspecific binding was determined in the same conditions but with the addition of 100 M GTP␥S. Reactions were incubated for 30 min at 30°C and were terminated by the addition of 0.5 ml of ice-cold buffer, containing 20 mM HEPES, pH 7.4, 3 mM MgCl 2 , and 100 mM NaCl. The samples were centrifuged at 16,000g for 15 min at 4°C, and the resulting pellets were resuspended in solubilization buffer (100 mM Tris, 200 mM NaCl, 1 mM EDTA, 1.25% Nonidet P-40) plus 0.2% SDS. Samples were precleared with Pansorbin, followed by immunoprecipitation with in-house antisera raised against either the C terminus of either G␣ i2 or G␣ o1 . Finally, the immunocomplexes were washed twice with solubilization buffer, and bound [ 35 S]GTP␥S was measured by liquid scintillation spectrometry. ]GTP␥S binding assays were performed at room temperature in a 384-well format. Membranes (10 g/point) were diluted to 0.4 mg/ml in assay buffer (20 mM HEPES, 100 mM NaCl, 10 mM MgCl 2 , pH 7.4) supplemented with saponin (10 mg/l), preincubated with 10 M GDP and wheat germ agglutinin SPA beads (GE Healthcare) (0.5 mg), and incubated at room temperature for 45 min with agitation. Various concentrations of D 2 dopamine receptor agonists were added, followed by [ Data Analysis. Data were analyzed using Prism (GraphPad Software Inc., San Diego, CA), and statistical significance was determined using either Student's t test or ANOVA followed by the Bonferroni post-hoc analysis as appropriate. p Ͻ 0.05 Determined statistical significance. [
35 S]GTP␥S binding was analyzed using nonlinear regression with variable slope, in which neither top nor bottom values were constrained. No outlying values were excluded.
Results
The Use of a Chimeric D 3/2 Receptor to Investigate a Region of D 2L and D 3 Important for G Protein Coupling Selectivity. Such a chimera was generated, based on the human D 3 receptor sequence, in which a 12-amino acid segment of the C terminus of the third intracellular loop was replaced with the equivalent region of the human D 2L (Fig.  1) . The 12 amino acids are entirely different but are flanked by identical sequences to their C-terminal side, close to transmembrane domain (TM) VI, and N-terminal side. Signal transduction from both D 2 and D 3 dopamine receptors is generally pertussis toxin-sensitive and, therefore, mediated by one, or more, G i subclass G protein(s). There is significant endogenous G␣ i subunit expression in HEK293T cells. Consequently, to allow the investigation of coupling between specific receptor and G protein pairs, HEK293T cells were cotransfected with a dopamine receptor (D 2L , D 3 , or D 3/2 ) and either C352I G␣ i2 or C351I G␣ o1 , which are pertussis toxininsensitive, and treated with or without pertussis toxin (25 ng/ml) for the final 16 h before cell harvest. To determine the number of appropriately folded receptors in membranes of these cells, the high-affinity dopaminergic antagonist/inverse agonist, [
3 H]spiperone, was used in saturation binding studies. In D 2L cotransfections, a single population of high-affinity sites for [ 3 H]spiperone was observed with K d of approximately 0.04 nM (Table 1) . Receptor density, as indicated by the B max value, was approximately 3 to 4 pmol/mg membrane protein in all transfections. For both C352I G␣ i2 and C351I G␣ o1 cotransfections, there were no significant differences in K d or B max for membranes from the same transfection with or without pertussis toxin treatment. However, although no difference in K d was observed, a significantly higher receptor density was observed in C351I G␣ o1 cotransfections compared with C352I G␣ i2 transfections. (Table 1) . As for D 2L cotransfections, a significantly higher value of B max was observed for both D 3 and D 3/2 with C351I G␣ o1 compared with the equivalent C352I G␣ i2 cotransfection. Again, no significant difference in K d or B max was observed for membranes from the same transfection with or without pertussis toxin treatment. However, it was noted that only in the case of the D 3 receptor, a significant difference in K d for [
3 H]spiperone was dependent on whether C352I G␣ i2 or C351I G␣ o1 was coexpressed.
G protein expression was measured for both C352I G␣ i2 and C351I G␣ o1 cotransfections by Western blotting using antisera raised against the C-terminal decapeptide of the respective G protein ␣ subunit ( Fig. 2A) . HEK293T cell membranes transfected with equivalent amounts of pcDNA3 vector were included as a control. These demonstrated that both C352I G␣ i2 and C351I G␣ o1 were significantly overexpressed in all membrane preparations ( Fig. 2A) . Although pertussis toxin treatment did not affect levels of either C352I G␣ i2 or C351I G␣ o1 ( Fig. 2A) , there was significant variation in the levels of G protein ␣ subunit detected between different transfections ( Fig. 2A) .
[ A, HEK293T cells were transiently cotransfected with a pertussis toxininsensitive G protein (C352I G␣ i2 or C351I G␣ o1 ) and a dopamine receptor (D 2L , D 3 , or D 3/2 ). These cells were treated with or without pertussis toxin (PTX) (25 ng/ml) for the last 16 h before cell harvest. Cell membranes were prepared, resolved by SDS-polyacrylamide gel electrophoresis, and immunoblotted to detect either G␣ i2 or G␣ o1 . Receptor expression levels were estimated in [ 3 H]spiperone saturation binding studies (Table 1) were markedly higher for the D 3/2 receptor (Fig. 2, B and C) , this probably reflects the low levels of expression of the D 3/2 chimera (Table 1) and, therefore, the substantially greater amount of G protein added to the assays.
Alterations in GPCR/G protein ratio can result in substantial differences in agonist potency and apparent efficacy. Therefore, for any direct and detailed comparisons of pharmacological variation between different GPCRs, this must be controlled. To achieve this, two approaches were used. One approach was the generation of receptor-G protein fusion proteins. The fusion proteins have a major advantage in defining and equalizing the receptor/G protein ratio for each GPCR and G protein, but they are an inherently artificial system. Therefore, it was important to also examine the G protein coupling selectivity of D 2 , D 3 , and D 3/2 in a system expressing receptor and G protein as separate polypeptides. With this in mind, the first approach was the generation of cell lines that express the pertussis toxin-insensitive forms of G␣ i1 , G␣ i2 , G␣ i3 , or G␣ o1 in an inducible fashion.
Cell Lines That Can Express Pertussis Toxin-Insensitive Forms of G␣ i1 , G␣ i2 , G␣ i3 , or G␣ o1 in an Inducible Fashion. A series of HEK293 cell lines based on the Flp-In T-REx system (Milasta et al., 2006; Lane et al., 2007) were generated. In these, one of D 2L , D 3 , or D 3/2 was expressed stably and constitutively, whereas either C351I G␣ o1 or C352I G␣ i2 was cloned into the Flp-In locus, allowing their expression in an inducible fashion. In concert with pertussis toxin pretreatment, this provided an alternative system in which the dopamine receptor-mediated stimulation of [ (Fig. 3) . In support of the earlier studies, [ (Fig. 4) . Although entirely consistent with the data from the transient cotransfections, the markedly different levels of receptor expression in the various lines we were able to isolate indicated that these cells would not be appropriate for detailed studies on the pharmacology of biased agonism and relative efficacy.
Studies with Dopamine Receptor-Pertussis ToxinInsensitive Cys3 Ile Variant G Protein Fusions. To control relative levels of G protein and receptor expression, a series of dopamine receptor-G protein fusion proteins were generated. Constraining GPCR and G protein within a fusion protein defines the stoichiometry of expression of the two polypeptides as 1:1 and ensures their colocalization after expression . D 2L receptor-Cys3 Ile pertussis toxin-insensitive G␣ subunit fusion proteins have been described previously for each of G␣ i1 , G␣ i2 , G␣ i3 , and G␣ o1 . Using the same methodology, eight further dopamine receptor-Cys3 Ile G␣ subunit fusion proteins were generated (Fig. 5A ) by fusing both D 3 and D 3/2 to each of the Cys3 Ile pertussis toxin-insensitive variants of G␣ i1 , G␣ i2 , G␣ i3 , and G␣ o1 . After transient transfection of these constructs and before cell harvest, HEK293T cells were treated with pertussis toxin to cause ADP-ribosylation of endogenous forms of G␣ i and hence allow interaction between the receptor and G protein within the fusion protein to be studied in isolation. [ 3 H]Spiperone displayed a similar and high affinity for each of the D 2L -G protein fusion proteins with K d of some 0.04 nM, whereas receptor binding site density was approximately 1.5 pmol/mg membrane protein for each ( Table 2 ). These cells were treated with or without tetracycline (Tet.) (1.0 g/ml for 24 h). Cell membranes were prepared, resolved by SDS-polyacrylamide gel electrophoresis and immunoblotted to detect either G␣ i2 (A) or G␣ o1 (B). [ 35 S]GTP␥S assays were performed with immunocapture by appropriate antisera to establish whether the coupling selectivity of the D 2L , D 3 , and D 3/2 receptors observed in the transient cotransfection studies was preserved after G protein fusion. It was; for the C351I G␣ i1 fusions, significant stimulation by dopamine was produced by D 2L -C351I G␣ i1 and D 3/2 -C351I G␣ i1 , but not by D 3 -C351I G␣ i1 (Fig. 3B, i) . This pattern was repeated for C352I G␣ i2 and C351I G␣ i3 (Fig. 3B, ii and , both p-tyramine and S-(Ϫ)-3-PPP displayed agonism only for activation of C351I G␣ o1 , whereas 7-OH-DPAT displayed partial agonism at D 2L for each of C351I G␣ i1 , C351I G␣ i3 , and C351I G␣ o1 but not for C352I G␣ i2 ( Fig. 6; Table 3 ). For D 3 , each of the ligands tested displayed agonism only for C351I G␣ o1 ( Fig. 7; Table 4 ). However, for all of the agonists examined, with the exception of NPA, the measured potency at D 3 -C351I G␣ o1 was significantly higher than at D 2 -C351I G␣ o1 , (Tables 4 and 5) . Indeed, although as demonstrated previously , S-(Ϫ)-3-PPP was a weak partial agonist at D 2 -C351I G␣ o1 (21 Ϯ 2% efficacy), at D 3 -C351I G␣ o1 , it displayed 63 Ϯ 2% efficacy relative to dopamine ( (Table 6 ), this was not true for D 3/2 -C351I G␣ i1 (Table  6) , where neither m-tyramine nor R-(ϩ)-3-PPP displayed agonism.
Discussion
The D 2 and D 3 receptors exhibit high amino acid homology, particularly within the transmembrane domains, and consequently have similar pharmacology (Sokoloff et al., 1990) . There has been considerable interest in the contribution of the D 3 receptor to the action of antipsychotic drugs, particularly after the observation that schizophrenia is associated with a marked elevation of mesolimbic D 3 receptors (Gurevich et al., 1997; Joyce, 2001) . The G protein coupling of D 2 has been well characterized with a general consensus for promiscuous coupling to each of G␣ i1 , G␣ i2 , G␣ i3 , and G␣ o1 (Senogles, 1994; Watts et al., 1998; Ghahremani et al., 1999; Jiang et al., 2001; Gazi et al., 2003) . However, the G protein coupling profile of D 3 is poorly characterized (Ahlgren-Beckendorf and Levant, 2004 A, series of fusion proteins were generated by linking Cys3 Ile mutant, pertussis toxin-insensitive variants of G␣ i1 , G␣ i2 , G␣ i3 , and G␣ o1 in frame with the C-terminal tail of D 3 or D 3/2 . Equivalent fusions incorporating D 2 have previously been reported . B, HEK293T cells were transiently transfected with dopamine (D 2L , D 3 , or D 3/2 ) receptor-Cys3 Ile G ␣ subunit fusion protein cDNAs; i, dopamine receptor-C351I G␣ i1 ; ii, dopamine receptor-C352I G␣ i2 ; iii, dopamine receptor-C351I G␣ i3 ; iv, dopamine receptor-C351I G␣ o1 . Cells were treated with pertussis toxin (25 ng/ ml) 16 h before cell harvest. Membranes from these cells were used to measure basal [
S]GTP␥S binding (open bars) and the effect of 10
Ϫ4 M dopamine (filled bars) on this. At the end of assay, an immunoprecipitation step was incorporated using antisera raised against the C-terminal decapeptide of G␣ i1/2 (i and ii), G␣ i3 (iii), or G␣ o1 (iv). The significance of differences between basal and dopaminestimulated [ to G␣ o1 (Zaworski et al., 1999; Beom et al., 2004) , although Zaworski et al. postulated that efficient coupling to G␣ o1 required the expression of adenyl cyclase subtype V. However, this study is the first to assess coupling to each of the four G␣ i/o subunits directly and, in parallel, to explore pharmacological consequences of attempting to expand the G protein coupling profile of the D 3 receptor. Key to this process was maintaining a clearly defined receptor to G protein expression stoichiometry, and, despite using both a series of transient cotransfection studies and establishing cells lines stably expressing dopamine receptors that allowed regulated expression of a G protein, this was only possible by using GPCR-G protein fusion proteins. The defined 1:1 ratio of receptor and G protein allowed direct comparisons between coupling of the D 2 and D 3 receptors to each G␣ i/o subunit and detailed analysis of pharmacological characteristics of a previously studied D 3/2 chimera. The highly selective coupling of D 3 to G␣ o1 may reflect the high amino acid homology among G␣ i1 , 2 , and 3 (85-90%), whereas G␣ o1 has lower identity (between 70 and 73%) with each of these. Furthermore, because the C-terminal decapeptide of G protein ␣ subunits plays a key role in receptor selectivity, the closer relationship in this region between G␣ o1 and G␣ i3 is probably relevant to why G␣ i3 was activated by all of the ligands examined when fused to the D 3/2 chimera, whereas this was not true for G␣ i1 or G␣ i2 .
A comparison of the potencies and relative efficacies of various agonists at D 2L and D 3 generally indicated higher potency and, for partial agonists, higher efficacy at the D 3 receptor. Although the GPCR-G protein proteins were used to generate these data, it is important to highlight that G protein selectivity measures were in complete agreement when separate GPCRs and G proteins were either transiently cotransfected or when the Flp-In T-REx cell lines were used. However, because of the inability to define GPCR/G protein ratios adequately, these systems were not deemed as appropriate for the detailed pharmacological comparisons.
In addition to serving in a classic postsynaptic sensory role, D 3 is also a presynaptic autoreceptor that is expressed predominantly in parts of the brain involved with controlling Table 4 . (Joseph et al., 2002) . The higher potency of dopamine for D 3 relative to D 2 shown in this study is consistent with its action as a presynaptic autoreceptor. The D 3 receptor may therefore be anticipated to regulate dopamine release at lower dopamine concentrations than D 2 . Consistent with presynaptic D 3 autoreceptors signaling through G␣ o1 , the localization of G␣ i/o proteins has been shown to be different at post-and presynaptic densities, with G␣ o1 more prevalent at presynaptic densities (Aoki et al., 1992) . With the presynaptic role of the dopamine D 3 receptor in mind, it is interesting to consider the potential role D 3 may have in the action of S-(Ϫ)-3-PPP, an interesting antipsychotic drug. In a previous study, we demonstrated that S-(Ϫ)-3-PPP is a functionally selective ligand at the D 2L receptor, displaying agonism for activation of G␣ o1 , but antagonism for activation of G␣ i1-3 . Furthermore, S-(Ϫ)-3-PPP has been shown to be an agonist at presynaptic dopamine receptors but an antagonist at postsynaptic dopamine receptors (Arnt et al., 1983; Hjorth et al., 1983) . It is possible that S-(Ϫ)-3-PPP acts both through presynaptic dopamine D 2 and D 3 receptors coupled to G␣ o1 . It is noteworthy that the current studies demonstrate that S-(Ϫ)-3-PPP has significantly higher relative efficacy to activate G␣ o1 as well as potency at D 3 compared with D 2L and therefore that D 3 may be the key target of S-(Ϫ)-3-PPP.
The molecular basis of G protein activation selectivity has been the focus of many studies (Wess, 1998; Wong, 2003) . However, despite the wealth of information regarding the Table 5 . coupling specificities of a multitude of GPCRs, no sequence homology has been obvious, even for GPCRs that couple to the same G protein subtype, and consensus motifs predictive of G protein coupling have been difficult to identify (Möller et al., 2001) . With the exchange of a 12-amino acid section of D 3 with the equivalent region from D 2 the D 3/2 , chimera stimulated [ 35 S]GTP␥S binding to each of G␣ i1 , G␣ i2 , G␣ i3 , and G␣ o1 in response to dopamine as opposed to the specific coupling of D 3 to G␣ o1 . Previous studies using this construct reported gain of adenylate cyclase inhibition in a system in which D 3 was unable to produce this effect (Filteau et al., 1999) . It would seem that this observed gain in the ability to inhibit adenylate cyclase lies at the level of the improved ability to couple to one, or more, of G␣ i1 , G␣ i2 , and G␣ i3 .
Because all the ligands tested allowed coupling of D 3/2 to both G␣ o1 and G␣ i3 , whereas various ligands were unable to activate either G␣ i1 or G␣ i2 via the chimeric receptor, it may now be possible to assess the contribution of different, coexpressed G i proteins to this endpoint in a direct and pharmacologically defined manner. A characteristic of the 12-amino acid segment that was swapped into D 3 is that nine aliphatic or hydrophobic amino acid residues in D 3 are replaced by charged or polar groups from the D 2 sequence. In contrast, the flanking sequences to this region (EKKATQ, close to TMVI, and the N-terminal TSL) are fully conserved between D 3 and D 2 , so exchange of this region is unlikely to disrupt overall receptor structure. It has been suggested that the C-terminal portion of the third intracellular loop of GPCRs Table 6 . forms a short ␣-helix that is extremely important for the interaction with heterotrimeric G proteins (Burstein et al., 1995; Wade et al., 1996) . It is possible that proline residues present in this portion of the third intracellular loop of D 3 disrupt such ␣ helical structure. The affinity for the antagonist/inverse agonist [ 3 H]spiperone at D 3/2 and the potency of ligands when the chimera was linked to G␣ o1 were not significantly different from that of D 3 coupled to G␣ o1 , again in agreement with previous work (McAllister et al., 1993; Filteau et al., 1999) . However, the potency of dopamine was markedly lower when the D 3/2 chimera was coupled to G␣ i1 or G␣ i2 compared with G␣ i3 or G␣ o1 . G␣ i3 has greater sequence similarity to G␣ o1 compared with that of G␣ i1 or G␣ i2 , in the extreme C terminus, a region long appreciated to be important in receptor-G protein coupling (Wess, 1998; Slessareva et al., 2003) . The different rank order of dopamine potency observed at the D 2 receptor (G␣ o1 Ͼ G␣ i1 ϭ G␣ i2 ϭ G␣ i3 ) versus D 3/2 (G␣ i3 ϭ G␣ o1 Ͼ Ͼ G␣ i1 or G␣ i2 ) could point toward a difference in coupling specificity. This perhaps indicates that additional sites within the D 2 receptor contribute to G protein coupling specificity, particularly in relation to coupling to G␣ i1 and G␣ i2 . In support of this, both N-and C-terminal portions of the third intracellular loop are capable of supporting functional coupling of D 2 to adenylate cyclase, but both are required for maximal coupling (Lachowicz and Sibley, 1997) . A reciprocal chimera to the one used in this study showed only a reduction in the potency of coupling to adenylate cyclase compared with D 2 rather than a complete abolition of coupling, indicating the presence of additional G protein coupling domains within the D 2 receptor (Filteau et al., 1999) . This is further supported by recent studies in which a peptide corresponding to the Nterminal region of the third intracellular loop of D 2L was able to activate G␣ i1 (Nanoff et al., 2006) .
Overall, these studies illustrate ways in which GPCR-G proteins fusions can be used to tease out and explore differences in pharmacology and function of closely related receptors and indicate that many prototypic D 2 -like agonist ligands display a degree of selectivity for D 3 over D 2 . However, because D 3 couples exclusively to G o , the range of signaling pathways likely to be activated by such ligands in vivo will be greater via the D 2 receptor. 
